FindTrial
Sign In

An applied study of small-dose methylprednisolone combined with tranexamic acid in the rapid rehabilitation of total hip arthroplasty

An applied study of small-dose methylprednisolone combined with tranexamic acid in the rapid rehabilitation of total hip arthroplasty

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300074764
Enrollment
Unknown
Registered
2023-08-15
Start date
2023-08-21
Completion date
Unknown
Last updated
2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Total hip replacement

Interventions

Methylprednisolone and tranexamic acid group :Methylprednisolone and tranexamic acid
Tranexamic acid group:Tranexamic acid

Sponsors

Hezhou People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 100 Years

Inclusion criteria

Inclusion criteria: Patients with signed informed consent for primary unilateral total hip arthroplasty

Exclusion criteria

Exclusion criteria: Allergy to methylprednisolone, tranexamic acid, rheumatoid arthritis, infected patients, body mass index (BMI) >30 kg/m2, one-stage bilateral hip replacement, revision surgery, coagulation abnormalities, haematological disorders, malignant neoplasm, severe cardiopulmonary disease, severe liver and renal abnormalities, history of previous thromboembolism, pre-operative haemoglobin less than 90 g/L, use of anti-coagulant medication in the last seven days prior to the operation.

Design outcomes

Primary

MeasureTime frame
CRP;IL-6;Glucose fluctuations;—

Countries

China

Contacts

Public ContactZuqi Huang

Hezhou People's Hospital

1076776537@qq.com+86 191 9786 1621

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026